Published July 5, 2005 | Version v1
Journal article

Dominant negative selection of vaccinia virus using a thymidine kinase/thymidylate kinase fusion gene and the prodrug azidothymidine

  • 1. Baxter BioScience/Vaccines, Biomedical Research Center, Uferstrasse 15, A-2304 Orth/Donau (Austria)

Description

The Escherichia coli thymidine kinase/thymidylate kinase (tk/tmk) fusion gene encodes an enzyme that efficiently converts the prodrug 3'-azido-2',3'-dideoxythymidine (AZT) into its toxic triphosphate derivative, a substance which stops DNA chain elongation. Integration of this marker gene into vaccinia virus that normally is not inhibited by AZT allowed the establishment of a powerful selection procedure for recombinant viruses. In contrast to the conventional vaccinia thymidine kinase (tk) selection that is performed in tk-negative cell lines, AZT selection can be performed in normal (tk-positive) cell lines. The technique is especially useful for the generation of replication-deficient vaccinia viruses and may also be used for gene knock-out studies of essential vaccinia genes

Additional details

Identifiers

DOI
10.1016/j.virol.2005.04.009;
PII
S0042-6822(05)00215-1;

Publishing Information

Journal Title
Virology
Journal Volume
337
Journal Issue
2
Journal Page Range
p. 235-241
ISSN
0042-6822
CODEN
VIRLAX

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
37037483
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
DNA; ENZYMES; ESCHERICHIA COLI; GENES; THYMIDINE; VACCINIA VIRUS
Descriptors DEC
AZINES; BACTERIA; HETEROCYCLIC COMPOUNDS; MICROORGANISMS; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; PARASITES; PROTEINS; PYRIMIDINES; RIBOSIDES; VIRUSES

Optional Information

Copyright
Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.